Browsing Tag

invIOs

invIOs presents exciting preclinical data showing that immune-activating small…

Eli Pacheco Jun 19, 2023 0

INV501, a potentially first-in-class compound, induces strong anti-tumor immune responses in preclinical models in different solid tumor indicationsTreatment with INV501 significantly…

Health

invIOs to present at upcoming industry and investor conferences

Eli Pacheco Oct 11, 2022 0

VIENNA, Austria, Oct. 11, 2022 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, today announces its participation…

Health

invIOs goes live with unique cell therapy platform and clinical-stage…

Eli Pacheco Dec 16, 2021 0

VIENNA, Austria, Dec. 16, 2021 (GLOBE NEWSWIRE) -- invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to…